The global organoids and spheroids market size was estimated to be USD 0.781 billion in 2023 and is anticipated to reach at USD 7.70 billion by 2034 with a CAGR of 23.12% during the forecast period 2024-2034. Growing emphasis on the development of organoids that replicate diseases such as chronic kidney disease, genetic disorders, colon cancer, & lung cancer, upswing in research & development activities, increasing advancements in technology for organoid models, rise in 3D spheroid technologies, genome editing technologies, & progress in stem cell research, surge in utilization of CRISPR/Cas9 gene editing technology, growing integration of microfluidics and automation, increasing mergers & acquisitions, rising approvals of innovative products, and surge in introduction of new organoids and spheroids products are some of the key factors boosting the market growth.
Surge in introduction of new organoids and spheroids products is predicted to boost the market growth during the forecast period. The field of life sciences research has seen the emergence of organoids and spheroids as relatively recent technologies, and their adoption and understanding are still in the process of evolution. Both organoids and spheroids represent three-dimensional cultured cell structures. Organoids, complex formations of organ-specific cells primarily sourced from the bladder, liver, and stomach, consist of stem or progenitor cells capable of self-assembly in a scaffolding environment. This results in the development of microscopic versions of the host organ, making organoids suitable for three-dimensional cell studies. In contrast, spheroids are derived from tumor tissues, mammary glands, hepatocytes, & embryoid bodies, which do not need scaffolding to self-assemble into three-dimensional cultures. For instance, in February 2023, TheWell Bioscience, a trailblazer in 3D cell culture platforms for precision medicine, cell therapy, and biomanufacturing, has introduced an innovative cell harvesting solution designed to enhance the speed and efficiency of recovering organoids and cells. The VitroGel Organoid Recovery Solution is groundbreaking, being the first solution capable of recovering organoids from both animal-based extracellular matrix (ECM) and synthetic VitroGel hydrogels.
By type, spheroids was the highest revenue-grossing segment in the global organoids and spheroids market in 2023 owing to a significant demand for applications in drug discovery, toxicology, & cancer research. The availability of commercially provided cell lines for spheroid generation is increasing, and there is a growing preference for utilizing products such as the LNCaP Cell Line and PC-3 Cell Line in the generation of spheroids. Additionally, organoids is predicted to grow at the fastest CAGR during the forecast period as organoids hold the potential to serve as in-vitro models for drug discovery, and increase in the introduction of new systems. For instance, in October 2022, The organiX System, developed by AIM Biotech Pte. Ltd., allows organoids to become vascularized and immunologically competent, extending their survival throughout the duration of the research.
By application, developmental biology was the highest revenue-grossing segment in the global organoids and spheroids market in 2023 owing to the rising utilization of organoid & spheroid culture systems in developmental biology, growing need for tools related to induced pluripotent stem cells (iPSCs) & Embryonic Stem Cells (ESCs) to explore tissue homeostasis, lineage specification, & embryonic development, and increasing trend of forming partnerships among key players. For instance, in August 2023, InSphero AG, a trailblazer in 3D cell-based assay technology, has revealed plans to offer its patented Akura Plate Technology to researchers in the US market. This initiative comes through a distribution agreement with Advanced BioMatrix, a prominent figure in the life sciences field specializing in 3D applications for tissue culture, cell assay, bioprinting, and cell proliferation. Additionally, regenerative medicine is predicted to grow at the fastest CAGR during the forecast period owing to the surge in research activities for the development of novel products. The transplantation of organoids and spheroids, originating from adult stem cells, facilitates the substitution of diseased tissue or organs.
By end-user, biotechnology & pharmaceutical companies was the highest revenue-grossing segment in the global organoids and spheroids market in 2023 owing to the increase in the adoption of organoids & spheroids for pre-clinical drug discovery by pharmaceutical companies, growing prevalence of chronic diseases such as cancer, chronic renal disease, & cardiovascular disease, and surge in the introduction of new products. For instance, in June 2023, AMSBIO has launched Matrimix, a novel 3D cell culture substrate featuring a fully defined formulation. This allows scientists to cultivate various tissues, offering a dependable and uniform extracellular matrix for cell culture. The introduction of this innovative product is anticipated to enhance organoid and spheroid research. Additionally, academic & research institutes is predicted to grow a the fastest CAGR during the forecast period owing to the increasing adoption in research related to developmental biology and disease modeling, surge in prevalence of various chronic diseases, and growing adoption of cutting-edge technologies.
North America region is anticipated for the highest revenue share during the forecast period owing to the rise in the use of organoid-based research models, growing advancements in technology, the presence of major industry players, increasing funding from international organizations, and surge in launch of new products. For instance, in March 2023, MIMETAS has introduced its Adult Stem Cell (ASC)-derived tubular organoids in a format ready for assay. Within its OrganoReady product line, MIMETAS provides two organoid-based products: ASC-derived Colon1 and Kidney2 Organoid tubules. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the continuous developments in stem cell research, increase in collaborations among major market entities, surge in innovations in 3D cell culture technology, expanding research initiatives in advanced cell models, and a growing number of partnerships and collaborations among industry players. For instance, in June 2023, Sydney-based biotech company Inventia Life Science, a renowned global leader in advanced cell models, has recently revealed a distribution agreement with Biotron Healthcare PVT Ltd. Through this collaboration, Biotron Healthcare PVT Ltd has secured the sales rights for Inventia Life Science's flagship RASTRUM platform, marking its entry into the Indian market.
Surge in introduction of new organoids and spheroids products is predicted to boost the market growth during the forecast period. The field of life sciences research has seen the emergence of organoids and spheroids as relatively recent technologies, and their adoption and understanding are still in the process of evolution. Both organoids and spheroids represent three-dimensional cultured cell structures. Organoids, complex formations of organ-specific cells primarily sourced from the bladder, liver, and stomach, consist of stem or progenitor cells capable of self-assembly in a scaffolding environment. This results in the development of microscopic versions of the host organ, making organoids suitable for three-dimensional cell studies. In contrast, spheroids are derived from tumor tissues, mammary glands, hepatocytes, & embryoid bodies, which do not need scaffolding to self-assemble into three-dimensional cultures. For instance, in February 2023, TheWell Bioscience, a trailblazer in 3D cell culture platforms for precision medicine, cell therapy, and biomanufacturing, has introduced an innovative cell harvesting solution designed to enhance the speed and efficiency of recovering organoids and cells. The VitroGel Organoid Recovery Solution is groundbreaking, being the first solution capable of recovering organoids from both animal-based extracellular matrix (ECM) and synthetic VitroGel hydrogels.
By type, spheroids was the highest revenue-grossing segment in the global organoids and spheroids market in 2023 owing to a significant demand for applications in drug discovery, toxicology, & cancer research. The availability of commercially provided cell lines for spheroid generation is increasing, and there is a growing preference for utilizing products such as the LNCaP Cell Line and PC-3 Cell Line in the generation of spheroids. Additionally, organoids is predicted to grow at the fastest CAGR during the forecast period as organoids hold the potential to serve as in-vitro models for drug discovery, and increase in the introduction of new systems. For instance, in October 2022, The organiX System, developed by AIM Biotech Pte. Ltd., allows organoids to become vascularized and immunologically competent, extending their survival throughout the duration of the research.
By application, developmental biology was the highest revenue-grossing segment in the global organoids and spheroids market in 2023 owing to the rising utilization of organoid & spheroid culture systems in developmental biology, growing need for tools related to induced pluripotent stem cells (iPSCs) & Embryonic Stem Cells (ESCs) to explore tissue homeostasis, lineage specification, & embryonic development, and increasing trend of forming partnerships among key players. For instance, in August 2023, InSphero AG, a trailblazer in 3D cell-based assay technology, has revealed plans to offer its patented Akura Plate Technology to researchers in the US market. This initiative comes through a distribution agreement with Advanced BioMatrix, a prominent figure in the life sciences field specializing in 3D applications for tissue culture, cell assay, bioprinting, and cell proliferation. Additionally, regenerative medicine is predicted to grow at the fastest CAGR during the forecast period owing to the surge in research activities for the development of novel products. The transplantation of organoids and spheroids, originating from adult stem cells, facilitates the substitution of diseased tissue or organs.
By end-user, biotechnology & pharmaceutical companies was the highest revenue-grossing segment in the global organoids and spheroids market in 2023 owing to the increase in the adoption of organoids & spheroids for pre-clinical drug discovery by pharmaceutical companies, growing prevalence of chronic diseases such as cancer, chronic renal disease, & cardiovascular disease, and surge in the introduction of new products. For instance, in June 2023, AMSBIO has launched Matrimix, a novel 3D cell culture substrate featuring a fully defined formulation. This allows scientists to cultivate various tissues, offering a dependable and uniform extracellular matrix for cell culture. The introduction of this innovative product is anticipated to enhance organoid and spheroid research. Additionally, academic & research institutes is predicted to grow a the fastest CAGR during the forecast period owing to the increasing adoption in research related to developmental biology and disease modeling, surge in prevalence of various chronic diseases, and growing adoption of cutting-edge technologies.
North America region is anticipated for the highest revenue share during the forecast period owing to the rise in the use of organoid-based research models, growing advancements in technology, the presence of major industry players, increasing funding from international organizations, and surge in launch of new products. For instance, in March 2023, MIMETAS has introduced its Adult Stem Cell (ASC)-derived tubular organoids in a format ready for assay. Within its OrganoReady product line, MIMETAS provides two organoid-based products: ASC-derived Colon1 and Kidney2 Organoid tubules. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the continuous developments in stem cell research, increase in collaborations among major market entities, surge in innovations in 3D cell culture technology, expanding research initiatives in advanced cell models, and a growing number of partnerships and collaborations among industry players. For instance, in June 2023, Sydney-based biotech company Inventia Life Science, a renowned global leader in advanced cell models, has recently revealed a distribution agreement with Biotron Healthcare PVT Ltd. Through this collaboration, Biotron Healthcare PVT Ltd has secured the sales rights for Inventia Life Science's flagship RASTRUM platform, marking its entry into the Indian market.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
Study Coverage
- Market Forecast by Type, Material, Product, and End-user
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of Top 10+ Major Market Players
- 20% Free Customization Available to Meet Your Exact Requirement.
Segmentation: Organoids And Spheroids Market Report 2023 - 2034
Organoids And Spheroids Market Analysis & Forecast by Type 2023 - 2034 (Revenue USD Bn)
- Spheroids
- By Type
- Mammospheres
- Hepatospheres
- Embryoid Bodies
- Neurospheres
- Multicellular Tumor Spheroids (MCTS)
- By Method
- Low Cell Attachment Plates
- Hanging Drop Method
- Micropatterned Plates
- Others
- By Source
- iPSCs Derived Cells
- Primary Cell
- Cell Line
- Organoids
- By Type
- Intestinal Organoids
- Hepatic Organoids
- Neural Organoids
- Other Organoids
- By Method
- Crypt Organoid Culture Techniques
- Clonal Organoids from Lgr5+ Cells
- Brain and Retina Organoid Formation Protocol
- Air Liquid Interface (ALI) Method for Organoid Culture
- General Submerged Method for Organoid Culture
- Others
- By Source
- Stem Cells
- Primary Tissues
Organoids And Spheroids Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Bn)
- Personalized Medicine
- Regenerative Medicine
- Disease Pathology Studies
- Developmental Biology
- Drug Toxicity & Efficacy Testing
Organoids And Spheroids Market Analysis & Forecast by End-user 2023 - 2034 (Revenue USD Bn)
- Academic & Research Institutes
- Hospitals and Diagnostic Centers
- Biotechnology and Pharmaceutical Industries
Organoids And Spheroids Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Organoids And Spheroids Market: Type Estimates & Trend Analysis
8. Organoids And Spheroids Market: Application Estimates & Trend Analysis
9. Organoids And Spheroids Market: End-user Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Organoids And Spheroids Market
12. Europe Organoids And Spheroids Market
13. Asia Pacific Organoids And Spheroids Market
14. Latin America Organoids And Spheroids Market
15. MEA Organoids And Spheroids Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Prellis Biologics
- 3D Biomatrix
- Hubrecht Organoid Technology (HUB)
- Lonza
- AMS Biotechnology (Europe) Limited
- Corning Incorporated
- STEMCELL Technologies Inc.
- InSphero
- Thermo Fisher Scientific Inc.
- 3D Biotek LLC
- Merck KGaA
- Cellesce Ltd.
- Greiner Bio-One
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | March 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 0.78 Billion |
| Forecasted Market Value ( USD | $ 7.7 Billion |
| Compound Annual Growth Rate | 23.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 13 |
